What Contamination Control Strategy (CCS) Means for Customer Confidence in Sterile Manufacturing
Contamination Control Strategy (CCS) has moved from regulatory checkbox to operational discipline across sterile manufacturing. But what does that shift actually look like inside a supplier’s operations, and why should customers care?
In this video interview, Aptar Pharma’s Nicolas Voisin and Audrey Chardonnet (Injectables division) discuss how CCS reshaped daily practice at Aptar Pharma, and what that means for the customers who rely on their sterile components.
The Aptar Pharma Injectables division, part of AptarGroup, Inc, develops and manufactures advanced closure components – such as vial stoppers, syringe plungers and rigid needle shields – for injectable drugs, helping pharmaceutical companies de-risk development and support the safe delivery of biologics, GLP-1 therapies, vaccines and other injectable medicines.
For More Information on APTAR Pharma Injectable Devices:
https://aptar.com/en-us/pharmaceutical/delivery-routes/injectables
Audrey Chardonnet is Vice President, Global Market Development for Aptar Pharma Injectables, leading teams across R&D and business development. With nearly two decades of experience in injectable drug delivery, she works at the intersection of customer needs, innovation, and market strategy, helping align future product development with evolving market expectations, industry trends, and regulatory requirements.
Nicolas Voisin is Global Quality Senior Director for Aptar Pharma Injectables and oversees quality across the division’s global operations. With more than two decades of experience in quality and manufacturing excellence across pharmaceutical, medical technology, and high-tech industries, his expertise spans contamination control, risk management, supplier quality, and quality system transformation.
Posted Date: 7/16/2026
This record has been viewed 342 times.
